InspiroGene
InspiroGene is McKesson's dedicated cell and gene therapy commercialization business unit, providing integrated 3PL, specialty distribution, specialty pharmacy, patient hub services, and the InspiroLink ordering platform to biopharma manufacturers across 95% of US CGT sites of care.
- Company typePrivate
- Founded2022
- HeadquartersIrving, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What InspiroGene does
InspiroGene is a wholly-owned business unit of McKesson Corporation (NYSE: MCK) that provides end-to-end commercialization services for cell and gene therapy (CGT) manufacturers. The platform integrates five service lines: Third-Party Logistics (3PL) with 12,000 sq ft of dedicated cryo/ultra-frozen storage within a 1 million sq ft Louisville, KY distribution center; Specialty Distribution with extensive treatment center coverage; Specialty Pharmacy with 50-state licensure and two redundant dispensing sites; the InspiroCare Patient Hub offering clinical case management, reimbursement support, and 24/7 care team access; and InspiroLink, a purpose-built ordering platform with API-level integrations across the CGT technology ecosystem. A distinguishing capability, Biologics-in-a-Box, co-locates specialty pharmacy dispensing within the 3PL environment to minimize manufacturer-to-treatment-center transit time. The unit covers 95% of active CGT sites of care and is staffed by teams with an average of 10+ years of CGT commercialization experience.
The company operates as a B2B enterprise service provider, targeting biopharma companies commercializing cell and gene therapies through a dedicated field sales motion and configurable engagement models (high-touch, configurable, or purpose-built). Revenue is generated through managed services fees, distribution and transaction fees, pharmacy dispensing fees, and biopharma-sponsored hub service agreements. Pricing is not publicly disclosed and is tailored per manufacturer. InspiroGene's named enterprise customers include Kite Pharma (CAR T-cell distribution), Vertex Pharmaceuticals (CASGEVY gene therapy distribution), Iovance Biotherapeutics (Amtagvi specialty pharmacy, the first FDA-approved cell therapy for solid tumors), Nanoscope Therapeutics (retinal gene therapy distribution), and Precigen (specialty pharmacy and patient hub for immunotherapy launch).
Strategically, InspiroGene leverages McKesson's Fortune 10 infrastructure, 300+ manufacturer relationships, $300B+ in annual WAC sales across full-line wholesale and specialty distribution, and a 450+ person multi-site logistics operation. The unit was launched in 2024 and has rapidly accumulated enterprise partnerships through 2026, supported by thought leadership content (annual CGT Report), industry event participation, and a marketing motion centered on positioning as an 'ally' to biopharma companies navigating CGT commercialization complexity. The platform's strategic intent is to capture share of the rapidly expanding CGT pipeline (235+ therapies analyzed in 2025) by offering integrated, CGT-specialized commercialization infrastructure that bridges the gap between therapy innovation and patient access.
InspiroGene firmographics
Firmographics- Name
- InspiroGene
- Legal name
- InspiroGene (Trademark of McKesson Corporation)
- Website
- https://inspirogene.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- InspiroGene is McKesson's dedicated cell and gene therapy commercialization business unit, providing integrated 3PL, specialty distribution, specialty pharmacy, patient hub services, and the InspiroLink ordering platform to biopharma manufacturers across 95% of US CGT sites of care.
- Ownership category
- akta.pro rank
InspiroGene industry classification
Industry- Product category
- Cell and Gene Therapy Commercialization Services
- NAICS
- Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
- SIC
- Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Biologics & Biosimilars Distributors (HLAIAJAH)
Keywords
Where InspiroGene is headquartered
LocationHeadquarters
- HQ city
- Irving
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
InspiroGene business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Third-Party Logistics (3PL) Services: Comprehensive 3PL services for CGT manufacturers including warehousing, distribution, transportation, customer service, and full order-to-cash services. Supports title and non-title distribution models with over $3B in annual revenue. Revenue generated through service fees for logistics, storage, kitting, and relabeling solutions.
- Specialty Distribution Services: Specialty distribution services with extensive treatment center coverage and optimized cash cycle management for CGT therapies. Revenue generated through distribution fees, logistics services, and financial management services.
- Specialty Pharmacy Services: End-to-end specialty pharmacy support for manufacturers, HCPs, payers, QTCs, and patients. Includes dispensing, reimbursement support, and patient management services. Revenue generated through pharmacy dispensing fees and service agreements.
- InspiroCare Patient Hub Services: Purpose-built patient HUB services providing clinical case management, reimbursement, education, and financial assistance coordination. Revenue generated through biopharma-sponsored hub service agreements.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
InspiroGene product offering
Product offeringCore offering
InspiroGene provides integrated commercialization services for cell and gene therapy (CGT) manufacturers, spanning third-party logistics (3PL) with cryo/cold-chain storage, specialty distribution, specialty pharmacy dispensing, and patient hub services (InspiroCare), all unified by the InspiroLink ordering platform. The offering is purpose-built for CGT commercialization, covering 95% of active US CGT sites of care and supporting biopharma manufacturers with end-to-end order-to-cash, reimbursement, and patient access workflows.
Product overview
InspiroGene by McKesson is a cell and gene therapy (CGT) commercialization platform offering an integrated suite of services. The core portfolio consists of five interconnected service lines: Third-Party Logistics (3PL) for storage, warehousing, and distribution; Specialty Distribution for treatment center coverage and logistics; Specialty Pharmacy for dispensing and patient management; InspiroCare Patient Hub for patient support and coordination; and InspiroLink as the central ordering and tracking platform. The platform is purpose-built for CGT with specialized features including cryo/ultra-frozen storage solutions, Biologics-in-a-Box for streamlined product transit, and a Drive-By pharmacy model. Supported by McKesson's established infrastructure and 10+ years of CGT expertise, the solution covers 95% of active CGT sites of care across the US.
Differentiator
Problem solved
Functional benefit
Brands
- InspiroCare: Patient HUB services for cell and gene therapy, providing personalized case management, financial assistance coordination, travel and logistics support, and educational resources for patients and caregivers.
- InspiroLink
Products and services
- Third-Party Logistics (3PL) Comprehensive third-party logistics services tailored for cell and gene therapy manufacturers, including cryo/ultra-frozen storage solutions, ordering systems, cash management, logistics, and data analytics; licensed across all 50 states and territories.
- Specialty Distribution Specialty distribution network with extensive treatment center coverage and optimized cash cycle management for cell and gene therapies, offering high-touch logistics and advanced data analytics.
- Specialty Pharmacy Purpose-built specialty pharmacy services dedicated to CGT for seamless site readiness, streamlined patient access and reimbursement processes, and high-touch dispensing with ongoing patient management; 50-state licensure with 2 redundant dispensing sites.
- InspiroCare Patient Hub Purpose-built patient hub services providing personalized, compassionate support to help patients, caregivers, and providers navigate the CGT journey, including clinical case management, reimbursement support, patient education, financial assistance coordination, and 24/7 access to the care team.
- InspiroLink Ordering Platform A purpose-built ordering application for healthcare providers ordering cell, gene, and advanced therapy treatments, supporting customized order workflows, scheduling, real-time product tracking, and API integrations across the Cell and Gene technology ecosystem.
- Treatment Center Experience Purpose-built support for CGT commercialization at treatment centers, including site readiness, efficient site activation, and reliable patient access, leveraging McKesson's national network of treatment centers.
Quantifiable outcome
- 95% of active CGT sites of care covered
- +6 more outcomes
Companies that use InspiroGene
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles2 records
InspiroGene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
InspiroGene partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Kite PharmacoreInspiroGene by McKesson expanded U.S. patient access to Kite's CAR T-cell therapies through a new distribution partnership. Kite is a Gilead Sciences company specializing in cell therapy for cancer treatment.
- Nanoscope TherapeuticscoreNanoscope Therapeutics selected InspiroGene to support distribution of its novel retinal therapy. The partnership enables Nanoscope to leverage McKesson's established distribution infrastructure.
- Iovance BiotherapeuticscoreInspiroGene was selected as specialty pharmacy partner for Iovance's Amtagvi (lifileucel), the first cell therapy approved for solid tumors. InspiroGene provides end-to-end specialty pharmacy support for the product.
- PrecigencoreMcKesson was selected to support specialty pharmacy and patient hub services for Precigen's novel immunotherapy launch. InspiroGene provides the specialized CGT capabilities for this partnership.
- Vertex PharmaceuticalscoreInspiroGene by McKesson partnered with Vertex to expand distribution options for CASGEVY (exagamglogene autotemcel), a gene therapy for sickle cell disease. This partnership extends patient access to Vertex's groundbreaking gene therapy.
- Biologics by McKessoncoreInspiroCare patient hub leverages the expertise of Biologics by McKesson to enhance both biopharma and patient experience throughout the CGT journey. Biologics provides the specialty pharmacy foundation and expertise for the integrated InspiroCare solution.
- LumanityminorLumanity is listed as a partner on the InspiroGene About page. Lumanity is a healthcare communications and patient engagement company.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
InspiroGene competitors and assessment
Company assessmentDirect peers
- World Courier (Cencora): Specialty pharmaceutical logistics and distribution provider (part of Cencora) with deep cold-chain capabilities serving cell and gene therapy manufacturers — a direct competitor to InspiroGene's 3PL and specialty distribution services.
- PCI Pharma Services: Specialty pharma services provider across sterile manufacturing, packaging, and global supply chain, with growing CGT capabilities — comparable to InspiroGene's specialty distribution and specialty pharmacy services for advanced therapies.
- Cryoport: Specialty logistics provider focused on temperature-controlled supply chain for cell and gene therapies, including cryogenic shipping and biostorage — directly comparable to InspiroGene's 3PL and cryo-storage capabilities for CGT manufacturers.
- Marken (UPS Healthcare): Global life sciences logistics provider offering temperature-controlled transportation, clinical trial logistics, and direct-to-patient services — competes with InspiroGene's 3PL and cold-chain distribution for cell and gene therapies.
Emerging players
- Vineti: Cloud-based CGT supply chain orchestration platform helping manufacturers, treatment centers, and patients manage cell therapy workflows — an emerging competitor with partial overlap on the digital/ordering layer to InspiroGene's InspiroLink platform.
- Yourway: Specialty biologic courier and clinical trial logistics provider with strong cold-chain and direct-to-patient capabilities — comparable to InspiroGene's transportation and cryo-logistics services for CGT products.
Broad incumbents
- Cencora (formerly AmerisourceBergen): Top-tier US pharmaceutical distributor with deep specialty distribution and patient services businesses (incl. World Courier, PharmaLex) — a broad incumbent that competes with McKesson and InspiroGene across CGT commercialization.
- Cardinal Health: Major US pharmaceutical distributor and specialty services provider with nuclear pharmacy and at-home specialty distribution capabilities — a broad incumbent competing with McKesson/InspiroGene in the broader specialty distribution market including CGT-adjacent products.
- Catalent: Large-scale CDMO and specialty pharma services provider with biologics development, manufacturing, and integrated clinical/commercial supply services — a broader incumbent with overlapping capabilities in CGT commercialization support.
- Syneos Health: Biopharma commercialization services provider with patient access, hub, and specialty pharmacy offerings — a broad incumbent that overlaps with InspiroCare's patient hub services for CGT manufacturers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
InspiroGene social profiles
Digital presenceInspiroGene financial estimates
Financial estimateRevenue estimate
Valuation estimate
InspiroGene leadership team
Management profileNumber of profiles
Profiles8 records
InspiroGene funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InspiroGene M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InspiroGene
What does InspiroGene do?
InspiroGene provides integrated commercialization services for cell and gene therapy (CGT) manufacturers, spanning third-party logistics (3PL) with cryo/cold-chain storage, specialty distribution, specialty pharmacy dispensing, and patient hub services (InspiroCare), all unified by the InspiroLink ordering platform. The offering is purpose-built for CGT commercialization, covering 95% of active US CGT sites of care and supporting biopharma manufacturers with end-to-end order-to-cash, reimbursement, and patient access workflows.
Is InspiroGene a public or private company?
InspiroGene is a private company. It is classified as corporate owned and is currently operating.
When was InspiroGene founded?
InspiroGene was founded in 2022. It employs 5,001 to 10,000 people.
Where is InspiroGene based?
InspiroGene is headquartered in Irving, United States, in the North America region.
How does InspiroGene make money?
Four revenue lines are on record. Third-Party Logistics (3PL) Services are the primary driver. The others are specialty Distribution Services, specialty Pharmacy Services and inspiroCare Patient Hub Services.
Who are InspiroGene's main competitors?
Direct peers on record are World Courier (Cencora), PCI Pharma Services, Cryoport and Marken (UPS Healthcare). Emerging players are Vineti and Yourway. Broad incumbents are Cencora (formerly AmerisourceBergen), Cardinal Health, Catalent and Syneos Health.
Does InspiroGene have an API?
No public API is recorded for InspiroGene.
What industry is InspiroGene in?
InspiroGene's product category is Cell and Gene Therapy Commercialization Services. Its primary akta.pro industry code is HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 524292 and its SIC code is 5047.